Title:
DEUTERATED PEPTIDOMIMETIC COMPOUND AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/125535
Kind Code:
A1
Abstract:
A compound having a deuterated peptidomimetic structure and a pharmaceutical composition containing same, and a use of the composition in prevention and/or treatment of diseases caused by RNA virus infection sensitive to a 3CL protease inhibitor and related diseases applicable to PAXLOVID. Compared with PF-07321332, the compound has higher plasma peak concentration and higher exposure in plasma, and has more excellent in-vivo pharmacokinetic behavior and higher antiviral activity.
Inventors:
SUN XIAOWEI (CN)
LIANG MIN (CN)
GUO XIAOFENG (CN)
ZHANG XIAOLIN (CN)
ZHANG HAOHAO (CN)
GAO NA (CN)
ZHAO JIE (CN)
DAN MO (CN)
HE YING (CN)
GAO YUAN (CN)
LIANG MIN (CN)
GUO XIAOFENG (CN)
ZHANG XIAOLIN (CN)
ZHANG HAOHAO (CN)
GAO NA (CN)
ZHAO JIE (CN)
DAN MO (CN)
HE YING (CN)
GAO YUAN (CN)
Application Number:
PCT/CN2022/142333
Publication Date:
July 06, 2023
Filing Date:
December 27, 2022
Export Citation:
Assignee:
CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN)
International Classes:
C07K5/093; A61K38/05; A61K38/06; A61K45/06; A61P31/14; C07K5/062
Domestic Patent References:
| WO2021250648A1 | 2021-12-16 | |||
| WO2021252644A1 | 2021-12-16 |
Foreign References:
| CN114805478A | 2022-07-29 | |||
| CN114426568A | 2022-05-03 | |||
| CN115385984A | 2022-11-25 |
Other References:
YINSHENG ZHANG: "Development of Deuterated Drug: Past, Present and Future", PROGRESS IN PHARMACEUTICAL SCIENCE, vol. 41, 25 December 2017 (2017-12-25), pages 902 - 918, XP093074580
Attorney, Agent or Firm:
BEIJING ORIGINTELLIGENCE IP LAW FIRM (CN)
Download PDF: